Mohyeldin M, Shrivastava S, Allu SVV. Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies. World J Cardiol 2024; 16(5): 269-273 [PMID: 38817647 DOI: 10.4330/wjc.v16.i5.269]
Corresponding Author of This Article
Moiud Mohyeldin, MD, Doctor, Staff Physician, Internal Medicine, University of Medical Sciences and Technology, Khartoum, Khartoum 11111, Sudan. moiudahmed@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. May 26, 2024; 16(5): 269-273 Published online May 26, 2024. doi: 10.4330/wjc.v16.i5.269
Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies
Moiud Mohyeldin, Shitij Shrivastava, Sai Vishnu Vardhan Allu
Moiud Mohyeldin, Internal Medicine, University of Medical Sciences and Technology, Khartoum 11111, Sudan
Shitij Shrivastava, Sai Vishnu Vardhan Allu, Internal Medicine, Bronxcare Health System, Bronx, NY 10457, United States
Author contributions: Mohyeldin M contributed to conceptualization, methodology, visualization, supervision, and project administration; Mohyeldin M takes responsibility for the integrity of the work as a whole, from inception to published article; Mohyeldin M, Shrivastava S and Allu SVV contributed to investigation, writing - original draft, and writing - review & editing; Shrivastava S and Allu SVV contributed to resources; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Moiud Mohyeldin, MD, Doctor, Staff Physician, Internal Medicine, University of Medical Sciences and Technology, Khartoum, Khartoum 11111, Sudan. moiudahmed@gmail.com
Received: February 21, 2024 Revised: April 23, 2024 Accepted: May 14, 2024 Published online: May 26, 2024 Processing time: 91 Days and 16.1 Hours
Abstract
Ibrutinib, a targeted therapy for B-cell malignancies, has shown remarkable efficacy in treating various hematologic cancers. However, its clinical use has raised concerns regarding cardiovascular complications, notably atrial fibrillation (AF). This comprehensive review critically evaluates the association between ibrutinib and AF by examining incidence, risk factors, mechanistic links, and management strategies. Through an extensive analysis of original research articles, this review elucidates the complex interplay between ibrutinib’s therapeutic benefits and cardiovascular risks. Moreover, it highlights the need for personalized treatment approaches, vigilant monitoring, and interdisciplinary collaboration to optimize patient outcomes and safety in the context of ibrutinib therapy. The review provides a valuable resource for healthcare professionals aiming to navigate the intricacies of ibrutinib’s therapeutic landscape while prioritizing patient well-being.
Core Tip: This review examines the association between ibrutinib, a Bruton’s tyrosine kinase inhibitor, and atrial fibrillation (AF). It explores the underlying mechanisms, clinical implications, and management strategies for AF in patients treated with ibrutinib. The article emphasizes the need for cardiovascular monitoring and alternative treatments to balance therapeutic efficacy and safety.
